ClinicalTrials.gg
CompletedNCT03681158Updated Apr 25, 2022

Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects

A Phase 1 interventional study of sodium valproate in Epilepsy, sponsored by Sanofi. Completed at 1 site in United Kingdom. Open to female participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
30 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing Valproic Acid in Epilepsy — 2 open to participants now, 3 under way, 1 of them phase 3. Valproic Acid · Epilepsy.

Enrollment
22nd of 23
5 · median 30
Started
2018
the only one that year
Phase 1
7 of 23
none open now
Registered
18th of 23
by date

Among the 23 studies testing Valproic Acid in Epilepsy, this one is the 22nd largest by enrollment, is the only one that started in 2018, is one of 7 in phase 1, and was the 18th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 23 studies testing Valproic Acid in Epilepsy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Valproic Acid

Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 30 Years to 60 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Valproic Acid in Epilepsy, or all of them as a file.
02

Study summary

Primary Objectives:

  • To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-sodium valproate (VPA) .
  • To determine the pharmacokinetics of sodium VPA and metabolite(s) and its contribution to the overall exposure of radioactivity.
  • To collect samples in order to determine the metabolic pathways of sodium VPA and identify the chemical structures and main excretion route of the main metabolites.

Secondary Objective:

To assess the clinical and biological tolerability of oral solution of sodium VPA.

Read the detailed description

Total study duration is 3 to 10 weeks, including a screening period of 8 to 28 days, treatment period of up to 15 days and a follow-up and end of study of up to 4 weeks.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects, between 30 and 60 years of age, inclusive.
  • Body weight between 40.0 and 90.0 kg, inclusive, between 18.0 and 30.0 kg/m2, inclusive.
  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
  • Normal vital signs after 10 minutes resting in supine position: 95 mmHg \< systolic blood pressure (SBP) \<140 mmHg or, for subjects over 45 years of age, \<150 mmHg, 45 mmHg \< diastolic blood pressure (DBP) \<90 mmHg, 40 bpm \< heart rate (HR) \<100 bpm
  • Standard 12-lead (ECG) parameters after 10 minutes resting in supine position in the following ranges; 120 ms\<PR\<220 ms, QRS\<120 ms, ≤450 ms and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not , or for subjects over 45 years of age, standard 12-lead ECG without clinically significant abnormality, in the judgment of the Investigator, with QTc≤470 ms.
  • Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects; however, serum creatinine, alkaline phosphatase, hepatic enzymes (, alanine aminotransferase), and total (unless the subject has documented Gilbert syndrome) should not exceed the upper laboratory norm.
  • Surgically and permanently sterile (hysterectomy, bilateral salpingectomy or bilateral salpingo-oophorectomy) at least 3 months earlier or . Menopause is defined as being amenorrheic for at least 2 years with plasma FSH level > 30 UI/L. No additional is required.
  • Having given written prior to undertaking any study-related procedure.
  • Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
  • Not under any administrative or legal supervision.
  • Normal renal function as expressed by a > 80 mL/min as calculated by the Cockroft and Gault formula

Exclusion criteria

Exclusion criteria:

  • Any subject with specific dietary habits, such as vegan.
  • Any subject with irregular bowel habits (more than 3 bowel movements/day or less than 1 every 2 days).
  • Any subject undergoing dental care or presenting with dental caries.
  • Any subject who is occupationally exposed to radiation as defined in the Ionising Radiations Regulations 2017.
  • Participation in a trial with 14C-radiolabelled medication in the 12 months preceding the study.
  • Radiation exposure, including that from the present study and radiopharmaceuticals or radionuclides in therapeutic or diagnostic procedures, but excluding background radiation, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years.
  • Poor metabolizer status for CYP2C9, CYP2C19, CYP2D6 (by genotyping).
  • Any consumption of citrus (grapefruit, orange, etc) or their juices within 5 days before inclusion.
  • Any to sodium VPA according to the applicable labeling (including personal or family history of severe hepatic dysfunction, urea cycle disorders, porphyria, to valproate, active liver disease, pregnancy, child bearing potential) and patients known to have mitochondrial disorders caused by mutations in the nuclear gene encoding mitochondrial enzyme polymerase γ (POLG, e.g. Alpers-Huttenlocher Syndrome).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    sodium valproate

    Single oral dose of sodium valproate containing \[14C\]-sodium VPA

    Drug: sodium valproate

Interventions

  • Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral

    Also known as: LA40220

06

What researchers measure

Primary outcomes

  1. Percentage of radioactive dose excreted in urine and feces

    Fractional and cumulative percentage of radioactive dose excreted in urine and feces

    Time frame: Day 1 to Day 43

  2. Assessment of key metabolite(s) of sodium valproate

    key metabolite(s) of sodium valproate will be assessed in plasma, urine and feces.

    Time frame: Day 1 to Day 43

  3. Assessment of PK parameters: Cmax

    Maximum plasma or blood concentration observed

    Time frame: Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

  4. Assessment of PK parameters: tmax

    Time to reach Cmax (tmax)

    Time frame: Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

  5. Assessment of PK parameters: AUClast

    Area under the plasma concentration versus time curve calculated from time zero to the real time, tlast (time corresponding to the last concentration above the limit of quantification, Clast (AUClast)

    Time frame: Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

  6. Assessment of PK parameters: AUC

    Area under the plasma concentration versus time curve extrapolated to infinity (AUC)

    Time frame: Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

  7. Assessment of PK parameters: t1/2z

    Terminal half-life associated with the terminal slope (λz) (t1/2z) in plasma, blood radioactivity and plasma VPA

    Time frame: Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

  8. Assessment of PK parameters: B/P (blood/plasma radioactivity ratio)

    Blood to plasma radioactivity ratio calculated at each time point

    Time frame: Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

  9. Assessment of PK parameters: RCmax (VPA to radioactivity ratio for plasma Cmax)

    RCmax is calculated as Cmax(VPA)/Cmax (radioactivity)

    Time frame: Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

  10. Assessment of PK parameters: RAUC (VPA to radioactivity ratio for plasma AUC)

    RAUC is calculated as AUC(VPA)/AUC (radioactivity)

    Time frame: Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

Secondary outcomes

  1. Safety- Adverse Events

    Adverse events, spontaneously reported by the subject or observed by the Investigator from day -1 to day 43

    Time frame: From day -1 to 43

07

Study locations

1 site
  • Investigational site number
    Nottingham, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Apr 2019, 6 months.

Of 34 industry-sponsored phase 1 interventional studies under Epilepsy, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 6 months is above that.

Counting every sponsor, half of 55 studies reached it within 8 months; a quarter within 3 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2018
First posted
Sep 21, 2018
StartActual
Oct 5, 2018
Primary completionActual
Apr 11, 2019
CompletionActual
Apr 11, 2019
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03681158
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 21, 2018
Start date
Oct 5, 2018
Primary completion
Apr 11, 2019
Completion
Apr 11, 2019
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion